» Articles » PMID: 30586411

BRCA Challenge: BRCA Exchange As a Global Resource for Variants in BRCA1 and BRCA2

Abstract

The BRCA Challenge is a long-term data-sharing project initiated within the Global Alliance for Genomics and Health (GA4GH) to aggregate BRCA1 and BRCA2 data to support highly collaborative research activities. Its goal is to generate an informed and current understanding of the impact of genetic variation on cancer risk across the iconic cancer predisposition genes, BRCA1 and BRCA2. Initially, reported variants in BRCA1 and BRCA2 available from public databases were integrated into a single, newly created site, www.brcaexchange.org. The purpose of the BRCA Exchange is to provide the community with a reliable and easily accessible record of variants interpreted for a high-penetrance phenotype. More than 20,000 variants have been aggregated, three times the number found in the next-largest public database at the project's outset, of which approximately 7,250 have expert classifications. The data set is based on shared information from existing clinical databases-Breast Cancer Information Core (BIC), ClinVar, and the Leiden Open Variation Database (LOVD)-as well as population databases, all linked to a single point of access. The BRCA Challenge has brought together the existing international Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) consortium expert panel, along with expert clinicians, diagnosticians, researchers, and database providers, all with a common goal of advancing our understanding of BRCA1 and BRCA2 variation. Ongoing work includes direct contact with national centers with access to BRCA1 and BRCA2 diagnostic data to encourage data sharing, development of methods suitable for extraction of genetic variation at the level of individual laboratory reports, and engagement with participant communities to enable a more comprehensive understanding of the clinical significance of genetic variation in BRCA1 and BRCA2.

Citing Articles

Saturation genome editing-based clinical classification of BRCA2 variants.

Sahu S, Galloux M, Southon E, Caylor D, Sullivan T, Arnaudi M Nature. 2025; 638(8050):538-545.

PMID: 39779848 DOI: 10.1038/s41586-024-08349-1.


Unveiling the Digital Evolution of Molecular Tumor Boards.

Lutz S, DAngelo A, Hammerl S, Schmutz M, Claus R, Fischer N Target Oncol. 2024; 20(1):27-43.

PMID: 39609355 PMC: 11762447. DOI: 10.1007/s11523-024-01109-1.


Genomic profiling and expanded use of targeted anticancer drugs in solid cancers with exhausted evidence-based treatment options (PRECODE): study protocol of a prospective, non-randomized, cohort study.

Hansen K, Lyng M, Kodahl A, Asmussen J, Arshad A, Petersen H BMC Med Genomics. 2024; 17(1):274.

PMID: 39574115 PMC: 11583735. DOI: 10.1186/s12920-024-02033-z.


BRCAIndica: a resource for ACMG/AMP classified BRCA1 and BRCA2 variants.

Vatsyayan A, Anu R, Mathur P, Uchil D, Joshi A, Dwivedi A Fam Cancer. 2024; 24(1):4.

PMID: 39546087 DOI: 10.1007/s10689-024-00429-5.


Two founder variants account for over 90% of pathogenic BRCA alleles in the Orkney and Shetland Isles in Scotland.

Kerr S, Klaric L, Muckian M, Cowan E, Snadden L, Tzoneva G Eur J Hum Genet. 2024; 32(12):1624-1631.

PMID: 39438716 PMC: 11607322. DOI: 10.1038/s41431-024-01704-w.


References
1.
Burn J, Watson M . The Human Variome Project. Hum Mutat. 2016; 37(6):505-7. DOI: 10.1002/humu.22986. View

2.
Spurdle A, Healey S, Devereau A, Hogervorst F, Monteiro A, Nathanson K . ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes. Hum Mutat. 2011; 33(1):2-7. PMC: 3240687. DOI: 10.1002/humu.21628. View

3.
Spurdle A, Whiley P, Thompson B, Feng B, Healey S, Brown M . BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk. J Med Genet. 2012; 49(8):525-32. PMC: 3810416. DOI: 10.1136/jmedgenet-2012-101037. View

4.
Arbustini E, Sgarella A, Ferrari A, Grasso D, Cassani C, Lucioni M . RE: BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. J Natl Cancer Inst. 2016; 108(12). DOI: 10.1093/jnci/djw172. View

5.
Shimelis H, Mesman R, von Nicolai C, Ehlen A, Guidugli L, Martin C . Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer. Cancer Res. 2017; 77(11):2789-2799. PMC: 5508554. DOI: 10.1158/0008-5472.CAN-16-2568. View